Investigator-initiated multi-institutional clinical trial of combination therapy of vaccination and gene-modified T cell targeting NY-ESO-1-antigen for refractory soft tissue sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Cancer vaccine NY-ESO-1 (Primary) ; NTBI 1301 (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms TriCombo study
- 03 Dec 2019 Status changed from recruiting to suspended.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 22 May 2018 Status changed from not yet recruiting to recruiting.